Form 4 for AKTX Akari Therapeutics Plc
Accepted 2025-10-24 00:00:00 ET · period of report 2025-10-22 · accession 0001493152-25-019194 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-24 | 2025-10-22 | AKTX | Farag Kameel D. | Interim CFO | A - Grant | $0.74 | +6,277 | 6,277 | New | +$4,645 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares representing Ordinary Shares | 2025-10-22 | A | A | 6,277 | $0.74 | 6,277 | D | — | — | (F1) Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer (F2) These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on October 31, 2025. |